Incanthera Plc · AQUIS:INC
Incanthera — Aquis Leading Lights Presentation June 2024
12 slides from Incanthera's conference presentation, June 2024
Slide 1: From Biotech Breakthrough to Partnership and Profitability
From Biotech Breakthrough to Partnership and Profitability Incanthera plc's Game-Changing Launch with the World’s Largest Health and Beauty Retailer ‘Aquis Leading Lights’ Presentation: June 2024 1
Slide 2: Disclaimer
Innovative Products for Dermatology and Oncology Disclaimer The information contained in these slides and any accompanying verbal presentation, any question and answer session and any document or material distributed at or in connection with the verbal presentation (together, the “Presentation”) hav
Slide 3: Introduction to Incanthera
Innovative Products for Dermatology and Oncology Introduction to Incanthera • Incanthera is a specialist company dedicated to innovative technologies in dermatology and oncology. • Established as a spin out from the Institute of Cancer Therapeutics, University of Bradford (UoB) in 2010, Incanthera h
Slide 4: Innovation into a Rapidly Growing Market
Innovative Products for Dermatology and Oncology Innovation into a Rapidly Growing Market • Incanthera’s IP, formulation expertise and delivery technologies: Skin + CELL: a unique skincare range • Skin+CELL is a revolutionary (biotech) skincare range Incanthera’s unique cutting-edge delivery technol
Slide 5: Cellular Repair
Innovative Products for Dermatology and Oncology CELLULAR REPAIR Bioactive Vit B3, also known as Niacinamide, is well established as playing a key role in energising the living cells of the skin, important in maintaining a natural healthy state and helping protect against adverse environmental chall
Slide 6: Commercial Deal Summary (RNS December 2023)
Innovative Products for Dermatology and Oncology Commercial Deal Summary ( RNS December 2023) Incanthera’s existing, unique and proven skin delivery technology has been developed into a range of luxury skincare products, following commercial discussions with Marionnaud, (part of A.S. Watson*). The n
Slide 7: Commercial Update (RNS March 2024)
Innovative Products for Dermatology and Oncology Commercial Update (RNS March 2024) • First order to generate revenue of c. £2m • First order doubled in size to 50,000 units: *One unit being one bottle of product i.e. face cream, hand cream etc. o Strong demand from customers anticipated by Marionna
Slide 8: Commercial Update (RNS June 2024)
Innovative Products for Dermatology and Oncology Commercial Update (RNS 3 June 2024) • Skin + CELL First Production Order Doubled Again to 100,000 units* • From original 25,000 announced Dec 2023 reflecting mounting anticipation • Launch September 2024 with extended Skin + CELL product range • First
Slide 9: Incanthera's Transformational Revenue Opportunity
Innovative Products for Dermatology and Oncology Incanthera’s Transformational Revenue Opportunity EUROPEAN ROLL OUT 1200 STORES 2025 2026 2027 2028 2029 2030 Av Unit Price (£) 34 35 35 35 35 35 Units sold 300,000 936,000 1,060,800 1,185,600 1,248,000 1,310,400 Revenue £m 10.1 32.8 37.1 41.5 43.7 45
Slide 10: Growth on Aquis: supported by IR and commercial newsflow
Innovative Products for Dermatology and Oncology Growth on Aquis:– supported by IR and commercial newsflow • Wealth of opportunity for commercial and financial RNS to support retail buying and share price • Proactive relationships with market makers and Aquis Exchange on IR/PR initiatives • Open com
Slide 11: Incanthera plc Shareholder Analysis
Innovative Products for Dermatology and Oncology Incanthera plc Shareholder Analysis Institutional, 19.81% Retail, 31.81%, University, 11.16% Management, 7.36% Venture capital, 17.63% Corporate, 12.23% Shareholder Percentage of shares Number of shares Institutional 19.81% 19,667,353 University 11.16
Slide 12: Investment Summary
Innovative Products for Dermatology and Oncology Investment Summary Commercial revenues from launch in September 2024 and subsequent roll out of deal with world’s largest health and beauty retailer Calendar Year 2024 will produce revenues in excess of £10 million, profitability and cash generation P
Incanthera — Aquis Leading Lights Presentation June 2024 on 6ix